On 8 October, researchers from Spain and the United States of America published an article on the application of a drug usually used to prevent blood clots and its effects in a mouse model of Alzheimer’s disease (AD) in the Journal of the American College of Cardiology. The team administered the drug dabigatran etexilate, respectively a placebo in both AD mice (TgCRND8) as well as their wild-type littermates over the course of a year. Conducting various tests over the course of the study, the team found that the AD mice who received the drug had less memory decline as well as less deposition of toxic fibirn than those AD mice who did not. Although it is clear that a translation of these effects in relatively small groups of mice cannot be translated to humans, these results warrant further potential investigation. Nevertheless, the authors also highlighted that there will be a need for caution when doing so, since anticoagulation drugs can also cause intracerebral haemorrhage in AD patients, which is linked to worse cognitive performance.